Featured news from NHIVNA
HIV-related news from NAM
Raltegravir has the edge over two protease inhibitors in three-drug comparison study
Gus Cairns, 2014-03-07 10:40:00
In a head-to-head comparison of three drugs presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) on Wednesday, the integrase inhibitor raltegravir (Isentress) proved to be superior, in terms of the overall likelihood of treatment failure, when compared to the two ritonavir-boosted protease inhibitors atazanavir (Reyataz) and darunavir (Prezista). All three drugs were taken alongside tenofovir and FTC (co-formulated in Truvada).
The superiority of raltegravir was not due to the likelihood of virological failure, which was not very different for the three drugs, but to discontinuations of the other two drugs, mainly due to gastrointestinal symptoms (both drugs) and to jaundice related to atazanavir. When virological failure and discontinuations were taken together as an overall measure of treatment failure, darunavir was also superior to atazanavir.
Source:1
